This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Saks, Cisco: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Archer Daniels Midland (ADM) downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynchs said. Favorable grains positions could reverse. $32 price target.

American Eagle (AEO) downgraded at Janney from Buy to Neutral, Janney Montgomery said. $15 price target. Channel checks continue to show weaker demand.

Alkermes (ALKS) upgraded at Leerink to Outperform, Leerink Swann said. ELN purchase should help augment organic growth potential.

Sotheby's (BID) downgraded at Craig-Hallum from Buy to Accumulate, Craig-Hallum said. Company is facing increased competition. $50 price target.

Calpine (CPN) upgraded at Dahlman Rose from Hold to Buy. $20 price target. Company has attractive exposure to California and Texas.

Cisco Systems (CSCO) rated new Buy at BGC Partners. $24 price target. Company has a solid balance sheet and is leveraged to growth in mobile video demand.

Diodes (DIOD) downgraded at BMO to Market Perform, BMO Capital Markets said. Valuation call, based on a $34 price target.

FirstEnergy (FE) price target raised at Citi to $41 from $36. Story improving but valuation reflects catalysts, Citigroup said. Maintain Hold rating.

FirstEnergy (FE) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Estimates also boosted, given better power market trends.

Gamco Investors (GBL) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $61 price target. Company is realizing higher organic growth.

GenOn Energy (GEN) downgraded at Dahlman Rose from Buy to Hold. Valuation call.

Jones Apparel (JNY) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. $11 price target. Estimates also cut, as the company is facing lower end-market demand.

Medivation (MDVN) initiated at Citi with a Buy rating and $35 price target. Biopharma with two promising phase 3 trials, Citigroup said.

Mindray Medical (MR) upgraded at Oppenheimer from Perform to Outperform. $32 price target. Company is seeing better operating momentum, with China driving overseas growth.

Ralcorp (RAH) downgraded at William Blair from Outperform to Market Perform, William Blair said. Expect little upside potential from the CAG bid.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs